# Efficacy and Safety of CSA and Avatrombopag for the Treatment of SAA in the Elderly

> **NCT05433922** · NA · UNKNOWN · sponsor: **Institute of Hematology & Blood Diseases Hospital, China** · enrollment: 80 (estimated)

## Conditions studied

- Severe Aplastic Anemia

## Interventions

- **DRUG:** Avatrombopag

## Key facts

- **NCT ID:** NCT05433922
- **Lead sponsor:** Institute of Hematology & Blood Diseases Hospital, China
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-06-01
- **Primary completion:** 2023-12-31
- **Final completion:** 2024-12-31
- **Target enrollment:** 80 (ESTIMATED)
- **Last updated:** 2022-06-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05433922

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05433922, "Efficacy and Safety of CSA and Avatrombopag for the Treatment of SAA in the Elderly". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT05433922. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*